Positive results for Phase III trial of risperidone extended-release subcutaneous injection for schizophrenia

In the RISE study, patients treated monthly (n=183) or once every two months (n=179) experienced a delay in time to relapse versus placebo (n=181), with relative reductions in risk of relapse of 80% and 62.5%, respectively (no absolute data reported).

Source:

Biospace Inc.